MedPath

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Pemetrexed+carboplatin
Registration Number
NCT05668988
Lead Sponsor
Dizal Pharmaceuticals
Brief Summary

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.

Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
320
Inclusion Criteria
  1. Aged at least 18 years old (or per local regulatory/IRB requirement).
  2. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy.
  3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation
  4. At least 1 measurable lesion per RECIST Version 1.1
  5. Life expectancy ≥ 12 weeks
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  7. Adequate organ and hematologic function
Exclusion Criteria
  1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC.
  2. Spinal cord compression or leptomeningeal metastasis.
  3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.
  4. History of stroke or intracranial hemorrhage within 6 months before randomization.
  5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sunvozertinibsunvozertinib-
Platinum-based ChemotherapyPemetrexed+carboplatin-
Primary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1Up to approximately 34 months after the first participant is randomized
Secondary Outcome Measures
NameTimeMethod
Overall SurvivalUp to approximately 34 months after the first participant is randomized

Trial Locations

Locations (160)

OPN Healthcare, Inc.

🇺🇸

Glendale, California, United States

Kaiser Permanente Medical Center

🇺🇸

Vallejo, California, United States

University of Colorado Hospital - Anschutz Cancer Pavilion

🇺🇸

Aurora, Colorado, United States

D&H Cancer Research Center

🇺🇸

Margate, Florida, United States

Brcr Global

🇺🇸

Plantation, Florida, United States

H. Lee Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

NYU Laura & Issac Perlmutter Cancer Center

🇺🇸

New York, New York, United States

Columbia University Medical Center

🇺🇸

New York, New York, United States

Gabrail Cancer Center Research

🇺🇸

Canton, Ohio, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Scroll for more (150 remaining)
OPN Healthcare, Inc.
🇺🇸Glendale, California, United States
Lam
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.